Acid control with esomeprazole and lansoprazole: A comparative dose–response study

Abstract

For low-, standard- and double-dose comparisons, esomeprazole achieved greater elevation of gastric pH and better acid control in more subjects than lansoprazole. Use of esomeprazole may therefore reduce the need for dose adaptations or drug switching.

Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy volunteers

“…dosing, the percentage of time that gastric pH was >4.0 was approximately 50% for EC E20 and 70% for EC E40. 15,18 Both of these dosages have also been approved for the risk reduction of NSAID-associated gastric ulcer. 16 In this study, PN 400 containing 20 or 30 mg of IR esomeprazole resulted in greater time with pH >4.0 over 24 h on day 9 than the control treatment of naproxen 500 mg b.d.…”

Esomeprazole Treatment of Frequent Heartburn: Two Randomized, Double-Blind, Placebo-Controlled Trials

“…12 Esomeprazole has been reported in several studies to be more effective than omeprazole, lansoprazole, and pantoprazole in relieving GERD-related heartburn symptoms and in acid control. [13][14][15][16][17][18][19] However, to date, esomeprazole has not been evaluated for OTC use as a remedy for frequent heartburn.…”

Management of reflux esophagitis: does the choice of proton pump inhibitor matter?

“…At the standard oral dose of 40 mg, esomeprazole has been shown to provide more effective acid control (intragastric pH > 4) than standard doses of lansoprazole (25)(26)(27)(28) or pantoprazole (25)(26)(27)29). Furthermore, at a maintenance dose of 20 mg, esomeprazole has also been shown to provide a significantly greater amount of time with pH > 4 than maintenance-dose lansoprazole (28,30) or pantoprazole (29,30). This effect is mirrored by higher rates of healing and lower rates of relapse in the large comparative clinical trials in the present analysis.…”

“…Healing rates in patients with RE receiving acid-suppressive therapy are directly related to the duration of time that intragastric pH > 4 can be maintained during treatment (21)(22)(23)(24). At the standard oral dose of 40 mg, esomeprazole has been shown to provide more effective acid control (intragastric pH > 4) than standard doses of lansoprazole (25)(26)(27)(28) or pantoprazole (25)(26)(27)29). Furthermore, at a maintenance dose of 20 mg, esomeprazole has also been shown to provide a significantly greater amount of time with pH > 4 than maintenance-dose lansoprazole (28,30) or pantoprazole (29,30).…”